The global embolotherapy market is projected to reach $4.8 billion by 2024, progressing at a CAGR of 8.0% during the forecast period.
Globally, the adoption of embolic procedures for the management of various diseases is increasing, owing to the rising healthcare spending and increasing patient pool. Furthermore, most of the patients who are diagnosed at intermediate stage and advanced stage, do not respond to curative therapies, such as ablation, surgical resection, and liver transplantation. Thus, increasing pool of patients, at an advanced stage of various life-threatening diseases, which require embolotherapy intervention, is a key driver supporting the growth of the embolotherapy market.
Globally, the North American embolotherapy market is expected to hold around 40% share by 2024. This can be mainly attributed to the rising cases of chronic diseases and increasing geriatric population.
Europe, APAC, LATAM, and Middle East and Africa are the other regions, which hold considerable shares in the embolotherapy market, on account of rising prevalence of cancer, and peripheral vascular and neurological diseases in these regions.
Manufacturers in the embolotherapy market are involved in product launches to increase their shares. For instance, in 2018, Medtronic Plc launched OptiSphere embolization spheres in the U.S., as well as Concerto 3D detachable coil system in Ireland.
Browse full report at: https://www.psmarketresearch.com/market-analysis/embolotherapy-market
Stryker Corporation, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems, Meril Life Sciences Pvt. Ltd., Kaneka Corporation, Johnson and Johnson, Cook Medical Inc., Boston Scientific Corporation, BTG Plc, Balt Extrusion, and Acandis GmbH and Medtronic Plc are some of the major players operating in the global embolotherapy industry.
No comments:
Post a Comment